Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Rogliani (Rome, Italy), J. Ora (Rome, Italy), M. Matera (Naples, Italy), M. Cazzola (Rome, Italy), L. Calzetta (Rome, Italy). Bidimensional comparative analysis of LABA/LAMA FDCs in COPD. 3378

Member's Comments

No comment yet.

Related content which might interest you: Switch from LABA+ICS to a LABA/LAMA combination in symptomatic women with COPD – an analysis of the observational DACCORD study Source: International Congress 2018 – Pharmacological management of COPD Year: 2018 Comparative efficacy of umeclidinium/vilanterol versus LABA/LAMA therapies in COPD: A network meta-analysis Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK Source: ERJ Open Res, 7 (1) 00480-2020; 10.1183/23120541.00480-2020 Year: 2021 Late Breaking Abstract - Impact of ICS/LABA and LABA/LAMA FDCs on lung function and exacerbation of COPD: a network meta-analysis Source: International Congress 2018 – Pharmacological management of COPD Year: 2018 Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: Pre-specified analysis on lung function and health status from the IMPACT trial Source: International Congress 2018 – COPD management Year: 2018 Low rate of exacerbations following initiation of LABA/LAMA fixed-dose combinations: An analysis of the DACCORD real life study Source: International Congress 2017 – COPD management Year: 2017 Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial Source: Annual Congress 2009 - Functional insights into COPD Year: 2009 Cost-effectiveness of fixed-dose combinations therapies for COPD in Spain Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017 LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment Source: Eur Respir Rev 2017; 26: 160043 Year: 2017 Effect of triple therapy with extra-fine BDP/FF/GB pMDI vs non-triple maintenance therapies on severe COPD exacerbations. A pooled analysis of the TRILOGY, TRINITY and TRIBUTE studies. Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020 Efficacy and safety of adding erdosteine in acute exacerbations of COPD (AECOPD): a comparative analysis with the standard treatment Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020 Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study Source: Eur Respir J 2010; 35: 532-539 Year: 2010 Clinical synergism of LABA/LAMA combinations in COPD patients Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017 Comparison of cardiovascular safety in a pooled analysis of COPD trials comparing tiotropium with salmeterol Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: The FLAME study Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial Source: International Congress 2018 – COPD management Year: 2018 Cost-effectiveness of antibiotics for COPD management: observational analysis using CPRD data Source: ERJ Open Res, 3 (2) 00085-2016; 10.1183/23120541.00085-2016 Year: 2017 Efficacy of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in COPD Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Effect of aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) on exacerbations in moderate-to-severe COPD: Pooled analysis of two studies Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Lung function with aclidinium/formoterol fixed-dose combination: Pooled analysis of two phase III studies in COPD Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015